



## MINUTES AND OVERVIEW PLAN

### CIBMTR WORKING COMMITTEE FOR ACUTE LEUKEMIA

Houston, TX

Friday, February 22<sup>nd</sup>, 2019, 12:15 – 2:45 pm

Co-Chair:	Marcos de Lima, MD, University Hospitals Case Medical Center, Cleveland, OH; Telephone: 216-286-6869; E-mail: marcos.delima@uhhospitals.org
Co-Chair:	Brenda Sandmaier, MD, Fred Hutchinson Cancer Research Center, Seattle, WA; Telephone: 206-667-4961; E-mail: bsandmai@fredhutch.org
Co-Chair:	Mark R. Litzow, MD; Mayo Clinic, Rochester, MN; Telephone: 206-667-4961; E-mail: litzow.mark@mayo.edu
Scientific Director:	Daniel J. Weisdorf, MD, University of Minnesota Medical Center, Minneapolis, MN; Telephone: 612-624-3101; E-mail: weisd001@umn.edu
Assistant Scientific Director:	Wael Saber, MD, MS, CIBMTR Statistical Center, Milwaukee, WI; Telephone: 414-805-0700; E-mail: wsaber@mcw.edu
Statistical Director:	Mei-Jie Zhang, PhD, CIBMTR Statistical Center, Milwaukee, WI; Telephone: 414-456-8375; E-mail: meijie@mcw.edu

---

#### 1. Introduction

The CIBMTR Acute Leukemia Working Committee was called to order at 12:15 pm on Friday, February 22<sup>rd</sup>, 2019, by Dr. Marcos de Lima. Attendees got their name badges scanned for attendance purposes and to maintain committee membership, and to fill out the Working Committee evaluations and voting sheets. The chairs, scientific director and statisticians were presented. Dr. Marcos de Lima introduced the conflict of interest disclosure statement, committee's accomplishments, ongoing studies and metrics for the past year. Dr. Wael Saber made a recognition to our leaving chair Marcos de Lima and Dr. Partow Kebriaei was introduced as incoming chair for the year 2019. Each proposal presentation was limited to 5 minutes to allow for adequate time for discussion (5 minutes).

#### 2. Accrual summary

Dr. Marcos de Lima briefly mentioned that the allo-HCT and auto-HCT accrued summary between 1995 and 2018 were in attachment 2 of the agenda without further details.

#### 3. Presentations published or submitted papers

Publication and presentations were mentioned but not presented.

- a. **LK15-02** Impact of GVHD on outcome after allogeneic hematopoietic cell transplantation for acute lymphocytic leukemia: a retrospective registry study (PI: M Yeshurun/ J Rowe/ M Tallman/ V Bachanova; MS: Hai-Lin Wang; PhD: Mei-Jie Zhang; oversight assignment: Sandmaier; Sci Dir: Weisdorf) **Accepted to Blood Advance 2018.**
- b. **LK15-01** AlloHCT vs other consolidation in elderly AML (PI: A Artz/ C Ustun; MS: Hai-Lin Wang; PhD: Jacob Allred; oversight assignment: Weisdorf; Sci Dir: Weisdorf). **ASH abstract for 2018. Submitted to Leukemia 2019.**

**Not for publication or presentation**

- c. **LK16-01** Reduced intensity conditioning regimens for acute myeloid leukemia: A comparison of busulfan and melphalan based regimens from the CIBMTR database (PI: Z Gul/ G Ahmed/ M Khan/ G Hilderbrandt/ H Alkhateeb/ M Damlaj/ M Patnaik/ R Nath/ Z Zhou/ J Cerny; MS: Khalid B.; PhD: Hai-Lin Wang; oversight assignment: Sandmaier; Sci Dir: Saber). **ASH abstract for 2018.**
- d. **LK16-04** Comparing outcomes between HLA-haploidentical and matched sibling allogeneic transplants in patients with acute myeloid leukemia (Rizwan Romee/ Armin Rashidi/ Mehdi Hamadani/ Wael Saber) **TCT oral presentation 2019.**

**4. Studies in progress**

The progress of other ongoing studies during the past year was not presented in order to provide more time for the new proposals' presentation and discussion. A summary of the progress was provided as an attachment to the committee members.

- a. **LK13-02** Prognostic significance of cytogenetic abnormalities in patients with Philadelphia - negative acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission (A Lazaryan/ V Bachanova/ D Weisdorf) **Manuscript preparation**
- b. **LK15-03** Comparison of outcomes of older adolescents and young adults with Philadelphia-chromosome/BCR-ABL1-negative acute lymphoblastic leukemia receiving post-remission consolidation chemotherapy with pediatric-inspired chemotherapy on CALGB 10403 or myeloablative allogeneic hematopoietic cell transplantation (M Wieduwilt/W Stock/ D Weisdorf).  
**Data File Preparation**
- c. **LK16-01** Reduced Intensity Conditioning (RIC) regimens for Acute Myeloid Leukemia (AML): A comparison of Busulfan (B) and Melphlan (M) based regimens from the CIBMTR database (Rajneesh Nath/ Zheng Zhou/ Jan Cerny) **Manuscript preparation**
- d. **LK16-02** DRI-guided Choice of Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes (Nelli Bejanyan/ Erica Warlick/ Claudio Brunstein/ Daniel Weisdorf) **Data File Preparation**
- e. **LK16-03** Allogeneic transplantation to treat therapy related acute myeloid leukemia and myelodysplastic syndromes (Natalie Callander/ Leland Metheny/ Marcos De Lima/ Aric Hall) **Data File Preparation**
- f. **LK16-04** Comparing outcomes between HLA-haploidentical and matched sibling allogeneic transplants in patients with acute myeloid leukemia (Rizwan Romee/ Armin Rashidi/ Mehdi Hamadani/ Wael Saber) **Manuscript preparation**
- g. **LK17-01** Outcomes of acute myeloid leukemia patients who undergo allogeneic transplant stratified by depth of clinical response (Mary-Elizabeth Percival/ Brenda Sandmaier/ Eli Estey) **Data File Preparation**
- h. **LK17-02** Allogeneic Hematopoietic Transplant Outcomes in Adult Patients with MLL-rearranged Acute Myeloid Leukemia (K Menghrajani/ M Tallman) **Protocol development**
- i. **LK17-03** Impact of post-transplant maintenance therapy with BCR-ABL tyrosine kinase inhibitors on outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia (Z DeFilipp/ YB Chen) **Protocol development**
- j. **LK18-01** Prognostic Impact of the new European LeukemiaNet Genetic Risk Stratification Categories in Predicting Outcomes for Adults with Acute Myeloid Leukemia undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Antonio Jimenez / Trent Wang / Marcos de Lima / Krishna Komanduri; MS: Jonathan Sanchez; PhD: TBD; oversight assignment: Litzow; Sci Dir: Weisdorf. **Protocol development**
- k. **LK18-02** Comparison of outcomes of HCT with matched-related donor or matched-unrelated donor alloHCT for adults with acute lymphoblastic leukemia (Matthew Wieduwilt / Leland

## ***Not for publication or presentation***

Metheny / Marcos de Lima; MS: Jonathan Sanchez; PhD: TBD; oversight assignment: de Lima; Sci Dir: Saber) **Protocol development**

### **5. Future/proposed studies**

Drs. Marco de Lima, Brenda Sandmaier and Mark R. Litzow led this session.

- a. **PROP 1808-01** Myeloablative or reduced intensity conditioning allogeneic hematopoietic transplantation in acute leukemia: CIBMTR analysis of long-term outcomes (Rammurti Kamble, Parameswaran Hari)  
Dr. Rammurti Kamble presented this proposal. There are 35,767 adult patients who underwent first allo-HCT for AML between 2005-2016 and 12,542 adult patients who underwent first allo-HCT for ALL between 2005-2016.  
The primary objective of this proposal was to compare TRM, DFS and OS at a 100 days, 1 year and 3 years for allo-HCT for Acute Leukemia base on their Conditioning intensity (MAC vs RIC). Comments were received to stratify the population between RIC, NMA and MAC. Also, the audience raised comment about the availability of karyotype and MRD information. Also concern regarding not learning anything new beyond what has already been published.
- b. **PROP 1810-01** Does the Novel Scoring System (I-CBFit) Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation in Core Binding Factor (CBF) AML with t(8;21)? (Celalettin Ustun)  
Dr. Celalettin Ustun presented this proposal. There are 624(TED: n=222; CRF: n=402) patients who underwent first allo-HCT for AML with available data regarding factors for the I-CBFit score. The specific aims of this study if to evaluate if I-CBFit predicts outcomes (Relapse,DFS and OS) after allogeneic HCT in patients with t(8;21) .  
Comments were received about MRD data availability.
- c. **PROP 1811-23** The influence of FLT3 internal tandem duplication vs flt3 tyrosine kinase domain with or without NPM1 or IDH1/2 on transplant outcome (Shatha Farhan/ Nalini Janakiraman/Edward Peres/Josephine Emole).  
Dr. Nalini Janakiraman presented this proposal on behalf of Shatha Farhan. There are 1,339 adult patients receiving First allo-HCT for AML between 2009-2017 with FLT3 ITD, IDH or NMP1 cytogenetic information. The objective of this proposal is to compare overall survival for patients FLT3/IDH dual mutants vs FLT3/IDH dual mutants.  
Comments were received about the association between the frequency of FLT3 and IDH. According to the discussion they were not associated. Also, there were comments regarding MRD data availability.
- d. **PROP 1811-41** Evolving significance of Ph-chromosome status on ALL prognosis in the TKI era (Maxwell Krem, Richard Maziarz)  
Dr. Maxwell Krem presented the proposal. There are 959 Ph- and 1,392 adult patients receiving first allo-HCT for ALL between 2001-2015. The primary objective of this study was to compare post-transplant outcomes of Ph-positive ALL patients vs Ph-negative ALL patients undergoing HCT over three time periods: 2001-2005, 2006-2010, 2011-2015.  
Comments were received regarding the patients that did not get to transplant it will not bring supporting data for the non-Transplant population. Also, suggestion was made for an internal validation control containing Ph- patients.
- e. **PROP 1811-106** Outcomes of alloHCT in AML patients who achieved complete remission after two or more cycles of induction chemotherapy (Michael Boyiadzis, Marcos de Lima)  
Dr. Michael Boyiadzis presented the proposal. There are 3,405 adult patients receiving first allo-HCT for AML in CR1 who received 2 or more cycles of induction chemotherapy between 2008-2015. I was hypothesize that the use of multiple cycles of induction chemotherapy causes

undue toxicity, which negatively impacts treatment-related mortality and survival following allo-HCT. The primary objective was to determine treatment-related mortality in patients who underwent allo-HCT in first CR that required 2 or more cycles of induction chemotherapy. Comments were made regarding the type of induction and dose, selection bias (patients made to HCT and got to CR) and suggested adjustment for number of consolidations before transplantation. Dr. Saber clarified that the purpose for this study would be to properly classify cases into different risk groups based on number of induction therapy received.

- f. **PROP 1811-113** Outcomes of alloHCT for adult acute lymphoblastic leukemia in a second or subsequent complete remission (Lyndsey Runaas, Guru Murthy)  
Dr. Lyndsey Runaas presented the proposal. There are 3,733 adult patients receiving first allo-HCT for ALL in CR2 or beyond between 2000-2016, reported to CIBMTR. The proponent hypothesize Outcomes of patients who underwent allogeneic hematopoietic cell transplantation (allo-HCT) for adult acute lymphoblastic leukemia (ALL) beyond first complete remission (CR) have remained historically poor. With the availability of effective salvage therapies, we postulate that the outcomes of these patients transplanted in second CR (CR2) or beyond would have improved over time. The primary objective is to assess the temporal trends in overall survival (OS) of ALL patients undergoing allo-HCT in CR2 or beyond. Comments were received to restrict to Ph- patients only considering new agents patients seems to have better outcomes and the new agents cohort is relevant to the most recent year which are a small subset of the population.
- g. **PROP 1811-137** Outcomes of acute lymphoblastic leukemia arising from a prior hematologic malignancy (Trent Wang, Antonio Jimenez)  
Dr. Trent Wang presented this proposal. There are 82 patients a history of malignancy receiving first allo-HCT for S-ALL between 2012-2016, reported to CIBMTR. Dr. Wang hypothesizes that s-ALL is an aggressive leukemia with poor outcomes. Allogeneic stem cell transplantation is employed when possible and can lead to durable remissions in this high-risk population. The primary objective is to evaluate outcomes (relapse, DFS, TRM and OS) for this population. Comments were made about adding other previous malignancies and expanding proposal to treatment related ALL.
- h. **PROP 1811-169** Comparison of outcomes of in vivo T-cell depleted versus T-cell replete donor grafts in reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation for older adults 60 years of age or older with acute myeloid leukemia (AML)  
Dr. Marc Schwartz presented this proposal. There are 282 TCD and 446 non-TCD adult older than 60 years receiving first RIC allo-HCT for AML in CR1 between 2000-2017, reported to CIBMTR. The primary objective of this study is to compare OS and Relapse between the following groups: (1) in vivo T cell depletion with Anti-Thymocyte Globulin (ATG), (2) in vivo T cell depletion with alemtuzumab, (3) no in vivo T cell depletion. Comments were received about the time to ATG, dose of ATG, center effect on TCD, overlap with GVWC ATG dosing study, donor shift in recent years rather than TCD practice change.
- i. **PROP 1811-170** Survival Probabilities of Patients with Acute Leukemias, Myelodysplastic Syndromes and Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplantation Conditional on Years Already Survived (Sudipto Mukherjee, Ronald Sobecks, Aaron Gerds)  
Dr. Sudipto Mukherjee presented this proposal. There are 9,211 Acute Leukemia, 2,676 MDS and 532 MF adult patients receiving first allo-HCT between 2000-2015. The primary objective of this study is to assess 5-year CS in 1-5 year survivors after allogeneic HCT for AL, MDS and MF.

**Not for publication or presentation**

Comments were received about the relevance of providing survival probabilities beyond 4-5 years after HCT given the patient already survived that long. There was suggestion to stratify analysis for patients with or without GVHD and expand to pediatric population.

- j. **PROP 1809-02** Evaluating outcomes of Hematopoietic Cell Transplantation in Blastic Plasmacytoid Dendritic Cell Neoplasm (Hemant Murthy)  
Dr. Hemant Murthy presented this proposal. There are 181 allo-HCT and 19 auto-HCT adult patients receiving first HCT for BPDCN between 2000-2017. Dr. Murthy hypothesizes that HCT is associated with durable remissions in patients with BPDCN. The primary objective of the study is to evaluate OS, PFS, NRM and Relapse for this population.  
Comments were received about specifying the type of induction received and expand to pediatric patients.
- k. **PROP 1811-86 / 1811-96** 10-year survival after allogeneic hematopoietic cell transplantation for AML in adults 60 years and above: frequency and success factors / 10 yr relapse-free survival in Acute myeloid leukemia in patients who underwent HCT in CR1. (Andrew Artz, Celalettin Ustun / Sumithira Vasu).  
Sumithira Vasu presented this proposal. There are 21697 patients with 18425 between 18-59 and 3373 older than 60. There are 9536 patients who underwent HCT between 2000-2004 and 12161 underwent HCT between 2005-2009. The primary objective of this study is to evaluate the long-term survival for AML patients after a allo-HCT.  
Comments were received about the accuracy of survival data after 10 years.

**Proposed studies; not accepted for consideration at this time**

These proposals were not discussed during the meeting. Dr. Daniel J. Weisdorf made comments about committee's busy portfolio and common reasons why proposals are not accepted for consideration. Attendees were encouraged to submit ideas again if not feasible at this time.

- a. **PROP 1808-01** Myeloablative or reduced intensity conditioning allogeneic hematopoietic transplantation in acute leukemia: CIBMTR analysis of long-term outcomes (Rammurti Kamble, Parameswaran Hari)
- b. **PROP 1810-01** Does the Novel Scoring System (I-CBfit) Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation in Core Binding Factor (CBF) AML with t(8;21)? (Celalettin Ustun)
- c. **PROP 1811-23** The influence of FLT3 internal tandem duplication vs flt3 tyrosine kinase domain with or without NPM1 or IDH1/2 on transplant outcome (Shatha Farhan/ Nalini Janakiraman/Edward Peres/Josephine Emole)
- d. **PROP 1811-113** Outcomes of alloHCT for adult acute lymphoblastic leukemia in a second or subsequent complete remission (Lyndsey Runaas, Guru Murthy)
- e. **PROP 1811-137** Outcomes of acute lymphoblastic leukemia arising from a prior hematologic malignancy (Trent Wang, Antonio Jimenez)
- f. **PROP 1811-169** Comparison of outcomes of in vivo T-cell depleted versus T-cell replete donor grafts in reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation for older adults 60 years of age or older with acute myeloid leukemia (AML)

**6. Other business**

- The advisory committee members Bart Scott and Michael Bishop were present during the working committee meeting and Bart Scott attended the pre and post meeting deliberations.
- During the post-meeting it was suggested to add MRD information availability in welcoming slides.

## **Not for publication or presentation**

- After the new proposals were presented, each participant in the meeting had the opportunity to rate each proposal using paper ballots. Based on the voting results, current scientific merit, available number or relevant cases and the impact of the study on the field, the following studies will move forward as the committee's research portfolio for the upcoming year:
  - **PROP 1809-02** Evaluating outcomes of Hematopoietic Cell Transplantation in Blastic Plasmacytoid Dendritic Cell Neoplasm (Hemant Murthy).
    - Include the person who presented this study in previous years as co-author/collaborator: Drs. Rafelson, Ganguly, Deotare, Ahmed and Nishihori
  - **PROP 1811-41** Evolving significance of Ph-chromosome status on ALL prognosis in the TKI era (Maxwell Krem, Richard Maziarz)
  - **PROP 1811-106** Outcomes of alloHCT in AML patients who achieved complete remission after two or more cycles of induction chemotherapy (Michael Boyiadzis, Marcos de Lima)

### **Working Committee Overview Plan for 2019 - 2020**

- a. **LK15-03:** Comparison of outcomes of older adolescents and young adults with Philadelphia-chromosome/BCR-ABL1-negative acute lymphoblastic leukemia receiving post-remission consolidation chemotherapy with pediatric-inspired chemotherapy on CALGB 10403 or myeloablative allogeneic hematopoietic cell transplantation. Data file preparation underway. (Total hour: 170; Allocated for the fiscal year: 70)
- b. **LK16-01** Reduced Intensity Conditioning (RIC) regimens for Acute Myeloid Leukemia (AML): A comparison of Busulfan (B) and Melphalan (M) based regimens from the CIBMTR database. Data file preparation is underway. Manuscript preparation is underway. The goal of the study is to have the manuscript submitted by July 2019. (Total hour: 70; Allocated for the fiscal year: 5)
- c. **LK16-02** DRI-guided Choice of Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Myeloid Leukemia and Myelodysplastic Syndromes. Data file preparation underway. The goal is to finalize the protocol and start data file preparation by June 2018 and finish analysis by June 2019. (Total hour: 160; Allocated for the fiscal year: 50)
- d. **LK16-03** Allogeneic transplantation to treat therapy related acute myeloid leukemia and myelodysplastic syndromes. Protocol development is underway. Data file preparation underway. The goal of the study is to finalize data analysis and manuscript preparation by July 2019. (Total hour: 160; Allocated for the fiscal year: 50)
- e. **LK17-01** Outcomes of acute myeloid leukemia patients who undergo allogeneic transplant stratified by depth of clinical response. Data file preparation underway. The goal of the study is to finalize data analysis and submit manuscript by July 2019. (Total hour: 140; Allocated for the fiscal year: 5)
- f. **LK17-02** Allogeneic Hematopoietic Transplant Outcomes in Adult Patients with MLL-rearranged Acute Myeloid Leukemia. Protocol development is underway. The goal of the study is to finalize data analysis and manuscript preparation by July 2019. (Total hour: 200; Allocated for the fiscal year: 70)
- g. **LK17-03** Impact of post-transplant maintenance therapy with BCR-ABL tyrosine kinase inhibitors on outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia. Protocol development is underway. The goal is to finalize the protocol, start data file preparation and analysis by July 2019. (Total hour: 280; Allocated for the fiscal year: 150)

**Not for publication or presentation**

- h. **LK18-01** Prognostic impact of ELN risk group in AlloHCT for adult AML in CR1/CR2. Protocol development is underway. The goal is to finalize the protocol and start data file preparation by July 2019. (Total hour: 280; Allocated for the fiscal year: 150)
- i. **LK18-02** Haplo vs RD vs MUD for adult ALL. Protocol development is underway. The goal is to finalize the protocol and start data file preparation by July 2019. (Total hour: 300; Allocated for the fiscal year: 180)
- j. **PROP 1809-02** Evaluating outcomes of Hematopoietic Cell Transplantation in Blastic Plasmacytoid Dendritic Cell Neoplasm (Hemant Murthy) (Total hour: 330; Allocated for the fiscal year:)
- k. **PROP 1811-41** Evolving significance of Ph-chromosome status on ALL prognosis in the TKI era (Maxwell Krem, Richard Maziarz) (Total hour: 330; Allocated for the fiscal year:100)
- l. **PROP 1811-106** Outcomes of alloHCT in AML patients who achieved complete remission after two or more cycles of induction chemotherapy (Michael Boyiadzis, Marcos de Lima) (Total hour: 330; Allocated for the fiscal year:100)

**Oversight Assignments for Working Committee Leadership (March 2019)**

Wael Saber	<b>LK17-02:</b> Allogeneic Hematopoietic Transplant Outcomes in Adult Patients with MLL-rearranged Acute Myeloid Leukemia
Partow Kebriaei	<b>LK18-02:</b> Comparison of outcomes of haploidentical hematopoietic cell transplantation (HCT) with matched-related donor or matched-unrelated donor allogeneic HCT for adults with Ph-negative acute lymphoblastic leukemia <b>LK19-02/PROP 1811-41:</b> Evolving significance of Ph-chromosome status on ALL prognosis in the TKI era
Brenda Sandmaier	<b>LK16-02:</b> DRI-guided choice of conditioning intensity for allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. <b>LK16-01:</b> Reduced intensity conditioning regimens for acute myeloid leukemia: A comparison of busulfan and melphalan based regimens from the CIBMTR database. <b>LK17-01:</b> Outcomes of acute myeloid leukemia patients who undergo allogeneic transplant stratified by depth of clinical response <b>LK19-03/PROP 1811-106:</b> Outcomes of alloHCT in AML patients who achieved complete remission after two or more cycles of induction chemotherapy
Mark Litzow	<b>LK17-03:</b> Impact of post-transplant maintenance therapy with BCR-ABL tyrosine kinase inhibitors on outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia <b>LK18-01:</b> Prognostic Impact of the new European LeukemiaNet (ELN) Genetic Risk Stratification Categories in Predicting Outcomes for Adults with Acute Myeloid Leukemia undergoing Allogeneic Hematopoietic Stem Cell Transplantation <b>LK19-01/PROP 1809-02:</b> Evaluating outcomes of Hematopoietic Cell Transplantation in Blastic Plasmacytoid Dendritic Cell Neoplasm

**Not for publication or presentation**

**Appendix: Overview Plan**

Study number and title	Current status	Goal with date	Total hours to complete	Total hours to goal	Hours allocated to 6/30/2018	Hours allocated 7/1/2018-6/30/2019	Total Hours allocated
LK13-02: Prognostic significance of cytogenetic abnormalities in patients with Ph- acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission	Submitted	Published - July 2019	10	10	10	0	10
LK15-01: Allogeneic transplants vs other consolidation in elderly AML	Submitted	Published- July 2019	10	10	10	0	10
LK15-02: Impact of GVHD on outcome after allogeneic hematopoietic cell transplantation for acute lymphocytic leukemia: a retrospective registry study	Published	Published- July 2019	0	0	0	0	0
LK15-03: Comparison of outcomes of older adolescents and young adults with Philadelphia-chromosome/BCR-ABL1-negative acute lymphoblastic leukemia receiving post-remission consolidation chemotherapy with pediatric-inspired chemotherapy on CALGB 10403 or myeloablative allogeneic hematopoietic cell transplantation	Data File Preparation	Manuscript Preparation- July 2019	170	100	100	70	170
LK16-01: Reduced intensity conditioning regimens for acute myeloid leukemia: A comparison of busulfan and melphalan based regimens from the CIBMTR database	Manuscript Preparation	Submitted- July 2019	70	70	70	0	70



***Not for publication or presentation***

LK16-02: DRI-guided choice of conditioning intensity for allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes	Analysis	Manuscript Preparation- July 2019	110	60	60	50	110
LK16-03: Allogeneic transplantation to treat therapy related acute myeloid leukemia and myelodysplastic syndromes	Analysis	Manuscript Preparation- July 2019	150	100	100	50	150
LK16-04: Comparing outcomes between HLA-haploidentical and matched sibling allogeneic transplants in patients with acute myeloid leukemia	Submitted	Published- July 2019	10	10	10	0	10
LK17-01: Outcomes of acute myeloid leukemia patients who undergo allogeneic transplant stratified by depth of clinical response	Data File Preparation	Submitted- July 2019	160	160	160	0	160
LK17-02: Allogeneic Hematopoietic Transplant Outcomes in Adult Patients with MLL-rearranged Acute Myeloid Leukemia	Data File Preparation	Manuscript Preparation- July 2019	200	130	130	70	200
LK17-03: Impact of post-transplant maintenance therapy with BCR-ABL tyrosine kinase inhibitors on outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia	Protocol Development	Analysis- July 2019	280	130	130	150	280

***Not for publication or presentation***

LK18-01: Prognostic Impact of the new European LeukemiaNet Genetic Risk Stratification Categories in Predicting Outcomes for Adults with Acute Myeloid Leukemia undergoing Allogeneic Hematopoietic Stem Cell Transplantation	Protocol Development	Analysis- July 2019	280	130	130	150	280
LK18-02: Comparison of outcomes of HCT with matched-related donor or matched-unrelated donor alloHCT for adults with acute lymphoblastic leukemia	Protocol Development	Data File Preparation- July 2019	280	30	30	180	210
LK19-01: Evaluating outcomes of hematopoietic cell transplantation in blastic plasmacytoid dendritic cell neoplasm	Protocol Pending	Draft Protocol Received- July 2019	330	0	0	100	100
LK19-02: Evolving significance of Ph-chromosome status on ALL prognosis in the TKI era	Protocol Pending	Draft Protocol Received- July 2019	330	0	0	100	100
LK19-03: Outcomes of alloHCT in AML patients who achieved first complete remission after two or more cycles of induction chemotherapy	Protocol Pending	Draft Protocol Received- July 2019	330	0	0	100	100